99% Purity Cagrisema Semag Retatrutide Weight Loss Peptide Pharmaceutical Raw Material

Product Details
CAS No.: 1415456-99-3
Formula: C225h348n48o68
EINECS: 200-001-8
Gold Member Since 2023

Suppliers with verified business licenses

Audited Supplier

Audited by an independent third-party inspection agency

Fast Delivery
The supplier can deliver the goods within 15 days
Low MOQ
The MOQ for the supplier's products is 1
Customization from Samples
The supplier provides sample based customization services
Customization from Designs
The supplier provides design based customization services
to see all verified strength labels (10)
  • 99% Purity Cagrisema Semag Retatrutide Weight Loss Peptide Pharmaceutical Raw Material
  • 99% Purity Cagrisema Semag Retatrutide Weight Loss Peptide Pharmaceutical Raw Material
  • 99% Purity Cagrisema Semag Retatrutide Weight Loss Peptide Pharmaceutical Raw Material
  • 99% Purity Cagrisema Semag Retatrutide Weight Loss Peptide Pharmaceutical Raw Material
  • 99% Purity Cagrisema Semag Retatrutide Weight Loss Peptide Pharmaceutical Raw Material
  • 99% Purity Cagrisema Semag Retatrutide Weight Loss Peptide Pharmaceutical Raw Material
Find Similar Products

Basic Info.

Colour
White
Specification
g
Trademark
Qingye
Origin
China
HS Code
000000
Production Capacity
50000kg

Product Description

99% Purity Cagrisema Semag Retatrutide Weight Loss Peptide Pharmaceutical Raw Material

Product Name: Semag Retatrutide Cas No. 1415456-99-3 
Purity: 99% Formula weight: 4813.45
Package: Foil Bag Molecular formula: C225H348N48O68
MOQ: 1 Gram or 1 Box EINECS: 200-001-8
Transportation: By Air Grade Standard Top Quality
Sample Availiable Shelf Life 2 Years

Primary endpoints:

At week 32, the proportions of patients with HbA1c <7.0% and ≤6.5% were 89% and 75%, respectively, in the CagriSema group, 69% and 48%, respectively, in the sema group, and 69% and 48%, respectively, in the canaglitide group. 33% and 17%. Additionally, the mean change in HbA1c from baseline to week 32 was higher in the CagriSema group than in the canaglitide group (estimated treatment difference [ETD] -1.3 percentage points [95% CI -1.7 to -0.8]; P < 0.0001), but There was no difference compared with the sema group (ETD -0.4 percentage points [95% CI -0.8 to 0.0]; P=0.075).

The average changes in HbA1c in the 3 groups are:

CagriSema group: -2.2 percentage points;

Sema group: -1.8 percentage points;

Canaglitide group: -0.9 percentage points.


99% Purity Cagrisema Semag Retatrutide Weight Loss Peptide Pharmaceutical Raw Material
Secondary endpoints:

The average change in body weight from baseline to 32 weeks was higher in the CagriSema group than in the canaglitide group (P<0.0001) and the semag group (P<0.0001).


The average changes in body weight of the 3 groups are:

CagriSema group: -15.6%;

Sema group: -5.1%;

Canaglitide group: -8.1%.
99% Purity Cagrisema Semag Retatrutide Weight Loss Peptide Pharmaceutical Raw MaterialThe average change in fasting blood glucose from baseline to 32 weeks was higher in the CagriSema group than in the canaglitide group (P=0.0010), but there was no significant difference compared with the sema group (P=0.10).

The average changes in fasting blood glucose in the 3 groups are:

CagriSema group: -3.3 mmol/L;

Sema group: -2.5 mmol/L;

Canaglitide group: -1.7 mmol/L.

At baseline, the CagriSema group, sema group and canaglitide group spent 45.9%, 32.6% and 56.9% of their time within the range of 3.9~10.0 mmol/L respectively, and at week 32 they were 88.9% and 76.2 respectively. % and 71.7%.

 
Adverse events were reported by 21 (68%) subjects in the CagriSema group, 22 (71%) subjects in the sema group, and 24 (80%) subjects in the canaglitide group. The most common adverse events were mild or moderate gastrointestinal disorders. In addition, no grade 2 or 3 hypoglycemic events or fatal adverse events were reported in this study.

Overall, treatment with CagriSema resulted in clinically relevant improvements in glycemic control. The average change in HbA1c in the CagriSema group was greater than that in the canaglitide group, but there was no significant difference compared with the sema group. In addition, patients in the CagriSema group experienced significantly greater weight loss compared with the sema and canaglitide groups and were well tolerated. These data support a longer, larger Phase 3 study of CagriSema in this population.

99% Purity Cagrisema Semag Retatrutide Weight Loss Peptide Pharmaceutical Raw Material
Q1: Can I get some samples?
A:Yes, we can supply the free sample, but the shipping cost be paid by our customers.

Q2: How to start orders or make payments?
A:Proforma invoice will be sent first after confirmation of order, enclosed our bank information. Payment by T/T, Western Union, Money Gram.

Q3: How to confirm the Product Quality before placing orders?
1.You can get free samples for some products,you only need to pay the shipping cost or arrange a courier to us and take the samples.
2. You can tell us your product specifications and requests,we will manufacture the products according to your requests.

Q4:Is there a discount?
A:Different quantity has different discount.

Q5: How do you treat quality complaint?
A:Our quality control will reduce the quality problem to near zero. If there is a real
quality problem caused by us, we will send you free goods for replacement.

Q6:Do you Accept Sample Order?
A:Yes, we accept small order from 1g, 5g and 10g to evaluate quality of our goods.
99% Purity Cagrisema Semag Retatrutide Weight Loss Peptide Pharmaceutical Raw Material
99% Purity Cagrisema Semag Retatrutide Weight Loss Peptide Pharmaceutical Raw Material
99% Purity Cagrisema Semag Retatrutide Weight Loss Peptide Pharmaceutical Raw Material
99% Purity Cagrisema Semag Retatrutide Weight Loss Peptide Pharmaceutical Raw Material

Welcome to be our distinguished customer, please do not hesitate to contact us!
 
 
 

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now
Contact Supplier